Lobbyists for the U.S. generic pharmaceutical industry are pressing Congress to eliminate a patent law provision that they say unfairly benefits brand-name drug companies, the AP/Bergen Record reports. Under U.S. law, the first generic pharmaceutical company to successfully challenge a brand-name patent receives six months of market exclusivity. [click link for full article]
More...